[{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hackensack Meridian Health \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Compass Pathways","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hackensack Meridian Health \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian Health \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"||Cyclooxygenase","graph1":"Urology","graph2":"Phase IV","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cryopreserved Umbilical Cord Allograft","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ MEDSIR","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ MEDSIR"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||Exportin-1","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Convalescent Plasma","moa":"||Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Convalescent Plasma","moa":"||Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ US Department of Defense"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"MD Anderson Cancer Center | Iscador AG, Arlesheim, Switzerland. | Tackle Kids Cancer | Susan Zabransky Hughes Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ MD Anderson Cancer Center | Iscador AG, Arlesheim, Switzerland. | Tackle Kids Cancer | Susan Zabransky Hughes Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ MD Anderson Cancer Center | Iscador AG, Arlesheim, Switzerland. | Tackle Kids Cancer | Susan Zabransky Hughes Foundation"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Lombardi Comprehensive Cancer Center | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu PSMA-617","moa":"||PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Lombardi Comprehensive Cancer Center | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Lombardi Comprehensive Cancer Center | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Merck & Co"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Hackensack Meridian Health","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metoprolol Succinate","moa":"||Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"||Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain;","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Convalescent Plasma","moa":"||Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hackensack Meridian Health \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Hackensack Meridian Health
Details :
The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).
Reset All
